Although some RCTs suggested that myo-inositol supplementation could reduce the incidence of GDM in high-risk women [109–113], a Cochrane review in 2016 concluded that the evidence sustaining the role of myo-inositol supplementation in reducing insulin requirements, reducing plasma glucose and preventing adverse neonatal and pregnancy outcome is still insufficient [114]. Here, INS is linked to gestational diabetes.